Direct-Acting Antivirals for Pediatric Chronic Hepatitis C Virus Infection

Abstract

Clinical evidence showed that treatment with glecaprevir-pibrentasvir for children and adolescents with chronic hepatitis C virus infection was efficacious with an overall sustained virologic response 12 weeks after treatment near 100%. Glecaprevir-pibrentasvir treatment was well-tolerated as there were no serious adverse events or adverse events leading to treatment discontinuation. Most adverse events were mild. We did not find any studies that evaluated the cost-effectiveness of glecaprevir-pibrentasvir for the treatment of chronic hepatitis C virus infection in pediatric patients. We did not find any peer-reviewed studies that evaluated the clinical effectiveness of sofosbuvir-velpatasvir for the treatment of chronic hepatitis C virus infection in pediatric patients. Unpublished data in a conference abstract and clinical trial registry suggest effectiveness of sofosbuvir-velpatasvir, but the findings should be interpreted with cautions. We did not find any studies that evaluated the cost-effectiveness of sofosbuvir-velpatasvir for the treatment of chronic hepatitis C virus infection in pediatric patients.